500 related articles for article (PubMed ID: 28389255)
1. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
2. No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
Gadalla SM; Wang T; Loftus D; Friedman L; Dagnall C; Haagenson M; Spellman SR; Buturovic L; Blauwkamp M; Shelton J; Fleischhauer K; Hsu KC; Verneris MR; Krstajic D; Hicks B; Jones K; Lee SJ; Savage SA
Bone Marrow Transplant; 2018 Apr; 53(4):383-391. PubMed ID: 29269807
[TBL] [Abstract][Full Text] [Related]
3. Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia.
Gadalla SM; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Katki HA; Lee SJ; Savage SA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2276-2282. PubMed ID: 27641680
[TBL] [Abstract][Full Text] [Related]
4. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.
Gadalla SM; Wang T; Haagenson M; Spellman SR; Lee SJ; Williams KM; Wong JY; De Vivo I; Savage SA
JAMA; 2015 Feb; 313(6):594-602. PubMed ID: 25668263
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
6. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
7. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
Foran JM; Pavletic SZ; Logan BR; Agovi-Johnson MA; Pérez WS; Bolwell BJ; Bornhäuser M; Bredeson CN; Cairo MS; Camitta BM; Copelan EA; Dehn J; Gale RP; George B; Gupta V; Hale GA; Lazarus HM; Litzow MR; Maharaj D; Marks DI; Martino R; Maziarz RT; Rowe JM; Rowlings PA; Savani BN; Savoie ML; Szer J; Waller EK; Wiernik PH; Weisdorf DJ
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1102-8. PubMed ID: 23632091
[TBL] [Abstract][Full Text] [Related]
8. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
[TBL] [Abstract][Full Text] [Related]
10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia.
Wang Y; McReynolds LJ; Dagnall C; Katki HA; Spellman SR; Wang T; Hicks B; Freedman ND; Jones K; Lee SJ; Savage SA; Gadalla SM
Br J Haematol; 2020 Jan; 188(2):309-316. PubMed ID: 31426123
[TBL] [Abstract][Full Text] [Related]
12. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
14. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
16. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
17. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.
Sengsayadeth S; Labopin M; Boumendil A; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gatwood KS; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1406-1414. PubMed ID: 29678639
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
[TBL] [Abstract][Full Text] [Related]
19. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
20. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
